About Trillium Therapeutics (TSE:TR)
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Industry, Sector and Symbol:
- Trailing EPS: C($5.07)
- Return on Equity: -246.11%
- Return on Assets: -64.76%
- Outstanding Shares: 10,790,000
Frequently Asked Questions for Trillium Therapeutics (TSE:TR)
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
When will Trillium Therapeutics make its next earnings announcement?
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Reitmans Limited (RET), Teranga Gold (TGZ), Redknee Solutions (RKN), Absolute Software (ABT), Liquor Stores N.A. Ltd (LIQ), Peregrine Metals Ltd (PGM), Lydian International Limited (LYD), 5N Plus (VNP), Trilogy International Partners (TRL), Pure Technologies (PUR), Wesdome Gold Mines Ltd (WDO), IBI Group (IBG), Rocky Mountain Dealerships (RME), TSO3 (TOS), HNZ Group (HNZ), Cervus Equipment (CERV), Imperial Metals (III) and AirBoss of America Corp (BOS).
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 58)
- Henry Friesen M.D., Independent Director (Age 79)
How do I buy Trillium Therapeutics stock?
Shares of Trillium Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of Trillium Therapeutics stock can currently be purchased for approximately C$13.35.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$144.11 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TSE TR)MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Trillium Therapeutics (TSE:TR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Trillium Therapeutics (TSE:TR)
Analysts' Ratings History for Trillium Therapeutics (TSE:TR)
(Data available from 11/21/2015 forward)
|7/17/2017||HC Wainwright||Reiterated Rating||Buy|
|5/12/2017||Leerink Swann||Reiterated Rating||Outperform|
|11/4/2016||Bloom Burton||Reiterated Rating||Buy|
Earnings History for Trillium Therapeutics (TSE:TR)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Trillium Therapeutics (TSE:TR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Trillium Therapeutics (TSE:TR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Trillium Therapeutics (TSE TR)
Insider Trades by Quarter for Trillium Therapeutics (TSE TR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/22/2016||Calvin R Stiller||Director||Buy||9,000||C$11.11||C$100,026.00|
|3/21/2016||Eric L Sievers||Insider||Buy||23,020||C$8.21||C$188,994.20|
Latest Headlines for Trillium Therapeutics (TSE TR)
Financials are not available for this stock.
Trillium Therapeutics (TSE TR) Chart for Tuesday, November, 21, 2017